IP Library Granted Patent US 12,419,936
Granted Patent B2
US 12,419,936 · App. 17/854,986 · Granted Sep 23, 2025

Collagen peptide-based medicament compositions and devices and methods of production and use thereof

Inventors: Richard E. Schlumpf (Stuart, FL); Robert Baratta (Palm City, FL); Shawn Delorey (Charlotte, NC); David J. Calkins (Nashville, TN)
Assignee: SUSTAIN HOLDINGS, LLC
A61K38/39A61K9/0019A61K9/0048A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,936
App. No.
17/854,986
Granted
Sep 23, 2025
Kind
B2
Abstract

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior and posterior segment ocular diseases or disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases or disorders.

Claims (20)

1. A composition for treating a posterior segment ocular disease or disorder, a paraocular disease, disorder or medical condition, an extraocular disease, disorder or medical condition, or an anterior segment ocular disease or disorder, in a human or veterinary animal in need of treatment or prevention of said disease or disorder, said composition comprising (a) at least one collagen mimetic peptide (CMP) comprising of the amino acid sequence of SEQ ID NO: 6, and (b) one or more pharmaceutically suitable carriers, wherein said composition is formulated to deliver the at least one CMP to an eye of the human or veterinary animal to enable the CMP to intercalate into disrupted type I collagen in the eye.

2. The composition of claim 1 , wherein said at least one CMP is attached to at least one therapeutic compound (TC) to form a CMP-TC conjugate.

3. The composition of claim 1 , wherein said posterior segment ocular disease or disorder involves the retina, retinal blood vessels, retinal nerves or optic nerve.

4. The composition of claim 3 , wherein said posterior segment ocular disease or disorder involves the retinal epithelium.

5. The composition of claim 3 , wherein said posterior segment ocular disease or disorder is selected from the group consisting of macular degeneration, retinitis pigmentosa, a retinal tear, retinal detachment, retinopathy, retinal arterial or venous occlusion, optic neuritis, optic neuropathy and optic atrophy.

6. The composition of claim 5 , wherein said macular degeneration is selected from wet macular degeneration, dry macular degeneration and age-related macular degeneration.

7. The composition of claim 5 , wherein said retinopathy is diabetic retinopathy.

8. The composition of claim 1 , wherein said composition is formulated to deliver the at least one CMP to the eye conjunctivally or subconjunctivally.

9. The composition of claim 8 , wherein said composition is formulated to deliver the at least one CMP into the subconjunctival fornix.

10. The composition of claim 1 , wherein said composition is formulated as one or more drops of solution or a suspension that contains the composition.

11. The composition of claim 1 , wherein said composition is formulated for delivery via injection.

12. The composition of claim 1 , wherein said composition is formulated in the form of a coating on a solid material for implanting into an eye structure.

13. The composition of claim 1 , wherein said composition is formulated in the form of a wafer, film, gel, mesh or patch.

14. The composition of claim 1 , wherein said composition is attached to one or more spheres or nanoparticles for delivery to or into an eye structure.

15. The composition of claim 2 , wherein said at least one therapeutic compound comprises at least one reactive hydroxyl group capable of being cross-linked to said collagen mimetic peptide.

16. The composition of claim 2 , wherein said at least one therapeutic compound is selected from the group consisting of a steroidal anti-inflammatory drug, a nonsteroidal anti-inflammatory drug, a topical anesthetic, a vitamin or a derivative or precursor thereof, therapeutic enzyme or a therapeutic fragment thereof, an antibiotic, a therapeutic monoclonal antibody or a therapeutic fragment thereof, a therapeutic fusion protein, a prostaglandin analogue, a growth factor, a neuropeptide, an α-adrenergic antagonist, a β-adrenergic antagonist, a cell surface receptor antagonist, a carbonic anhydrase inhibitor, and pharmaceutically acceptable salts, esters and derivatives thereof.

17. The composition of claim 2 , wherein said collagen mimetic peptide is covalently attached directly to said at least one therapeutic compound.

18. The composition of claim 2 , wherein said collagen mimetic peptide is indirectly attached to said at least one therapeutic compound via use of an attachment means.

19. The composition of claim 2 , wherein said collagen mimetic peptide comprises at least one biotin moiety and said therapeutic molecule comprises at least one avidin or streptavidin moiety, and wherein said biotin moiety on said collagen mimetic peptide binds to said avidin or streptavidin moiety on said therapeutic compound, thereby attaching said collagen mimetic peptide to said therapeutic compound.

20. The composition of claim 2 , wherein said collagen mimetic peptide comprises at least one avidin or streptavidin moiety and said therapeutic molecule comprises at least one biotin moiety, and wherein said avidin or streptavidin moiety on said collagen mimetic peptide binds to said biotin moiety on said therapeutic compound, thereby attaching said collagen mimetic peptide to said therapeutic compound.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2022
From: SCHLUMPF, RICHARD E.; BARATTA, ROBERT; DELOREY, SHAWN; CALKINS, DAVID J.
To: SUSTAIN HOLDINGS, LLC
Reel/Frame 061234/0959 →
Continuity (5)
Division 16855097 · Apr 22, 2020
Provisional Application 62959282 · Jan 10, 2020
Provisional Application 62933685 · Nov 11, 2019
Provisional Application 62836934 · Apr 22, 2019
Related Publication 20230048200A1 · Feb 16, 2023
References Cited (151)
US 5120764A · Mccarthy et al. · 1992 [cited by applicant]
US 5201456A · Reynal et al. · 1993 [cited by applicant]
US 5252608A · Palfreyman et al. · 1993 [cited by applicant]
US 5973112A · Raines et al. · 1999 [cited by applicant]
US 6197934B1 · Devore et al. · 2001 [cited by applicant]
US 6448378B2 · Devore et al. · 2002 [cited by applicant]
US 6946440B1 · Dewoolfson et al. · 2005 [cited by applicant]
US 7122521B2 · Raines et al. · 2006 [cited by applicant]
US 7402562B2 · Dewoolfson et al. · 2008 [cited by applicant]
US 7858741B2 · Raines et al. · 2010 [cited by applicant]
US 8283414B2 · Yu et al. · 2012 [cited by applicant]
US 8461303B2 · Smith et al. · 2013 [cited by applicant]
US 8658167B2 · Smith et al. · 2014 [cited by applicant]
US 8680246B2 · Mccauley et al. · 2014 [cited by applicant]
US 8883964B2 · Yu · 2014 [cited by examiner]
US 9072750B2 · Garrigue et al. · 2015 [cited by applicant]
US 9176139B2 · Smith et al. · 2015 [cited by applicant]
US 9255086B2 · Arora et al. · 2016 [cited by applicant]
US 9289396B2 · Devore et al. · 2016 [cited by applicant]
US 9289447B2 · Smith et al. · 2016 [cited by applicant]
US 9399102B2 · Dewoolfson et al. · 2016 [cited by applicant]
US 9623129B2 · Gonzales et al. · 2017 [cited by applicant]
US 9758569B2 · Raines et al. · 2017 [cited by applicant]
US 9988434B2 · Raines et al. · 2018 [cited by applicant]
US 10273287B2 · Phopase · 2019 [cited by applicant]
US 10532084B2 · Yang · 2020 [cited by applicant]
US 10632168B2 · Schlumpf · 2020 [cited by examiner]
US 11426440B2 · Schlumpf · 2022 [cited by examiner]
US 11433112B1 · Schlumpf · 2022 [cited by examiner]
US 11684651B2 · Schlumpf · 2023 [cited by examiner]
US 20070275897A1 · Raines et al. · 2007 [cited by applicant]
US 20080287342A1 · Yu et al. · 2008 [cited by applicant]
US 20110118349A1 · Garrigue et al. · 2011 [cited by applicant]
US 20120195828A1 · Nakamura et al. · 2012 [cited by applicant]
US 20130116405A1 · Yu · 2013 [cited by examiner]
US 20130116412A1 · Pinkas et al. · 2013 [cited by applicant]
US 20130129807A1 · Devore et al. · 2013 [cited by applicant]
US 20130164220A1 · Yu et al. · 2013 [cited by applicant]
US 20150111308A1 · Yu et al. · 2015 [cited by applicant]
US 20150209472A1 · Mccoy · 2015 [cited by applicant]
US 20160075764A1 · Raines et al. · 2016 [cited by applicant]
US 20160215018A1 · Yang et al. · 2016 [cited by applicant]
US 20180111979A1 · Phopase · 2018 [cited by applicant]
US 20180325977A1 · Schlumpf · 2018 [cited by examiner]
US 20180339024A1 · Bressler et al. · 2018 [cited by applicant]
US 20190002531A1 · Popel et al. · 2019 [cited by applicant]
US 20200179285A1 · Green et al. · 2020 [cited by applicant]
US 20200246415A1 · Schlumpf · 2020 [cited by examiner]
US 20230141917A1 · Schlumpf · 2023 [cited by examiner]
US 20230338458A1 · Schlumpf · 2023 [cited by examiner]
US 20240016900A1 · Baratta · 2024 [cited by examiner]
WO WO2018187530A1 · 2018 [cited by examiner]
Mix K “Chemical Methods for Protein Modification and Cellular Delivery” Doctoral Dissertation, University of Wisconsin-Madison, Maison, Wisconsin, USA. (Year: 2017). [cited by examiner]
Randall D “Graduate Student Spotlight: Jesus Dones” https://chemistry.mit.edu/chemistry-news/graduate-student-spotlight-jesus-dones/ (Year: 2018). [cited by examiner]
Abdelfattah et al., “Clinical correlates of common corneal neovascular diseases: a literature review,” International Journal of Ophthalmology (2015) 8(1):182-193. [cited by applicant]
Abelson et al., “Glaucoma and Dry Eye: A Tough Combo,” Rev. Ophthalmology (Oct. 2011), accessed Nov. 1, 2019 at URL: reviewofophthalmology.com/article/glaucoma-and-dry-eye-a-tough-combo, pp. 1-7 (Year: 2011). [cited by applicant]
Albu et al., “Collagen-Based Drug Delivery Systems for Tissue Engineering”, in: Biomaterials Applications for Nanomedicine, Prof. Pignatello, R. (Ed.), 2011, ISBN: 978-953-307-661-4, DOI: 10.5772/22981, Rijeka, Croatia:… [cited by applicant]
An et al., “Collagen interactions: Drug design and delivery,” Advanced Drug Delivery Reviews (2016) 97:69-84. [cited by applicant]
Bala et al., “PLGA nanoparticles in drug delivery: the state of the art.,” Critical Reviews in Therapeutic Drug Carrier Systems (2004) 21(5):387-422. [cited by applicant]
Bautista et al., “Insulin-like growth factors I and II are present in the skeletal tissues of ten vertebrates,” Metabolism (1990) 39(1):96-100. [cited by applicant]
Besseau et al., “Stabilization of Fluid Cholesteric Phases of Collagen to Ordered Gelated Matrices”, J. Mol. Biol. (1995) 251:197-202. [cited by applicant]
Bondareva et al., “The Lysyl Oxidase Inhibitor, β-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells,” PLoS ONE (2009) 4(6):e5620. [cited by applicant]
Bradley, “Some mechanical property considerations of reconstituted collagen for drug release supports”, Biomaterials, Medical Devices, and Artificial Organs (1997) 5(2):159-175. [cited by applicant]
Buechter et al., “Co-translational Incorporation of Trans-4-Hydroxyproline into Recombinant Proteins in Bacteria,” Journal of Biological Chemistry (2003) 278(1):645-650. [cited by applicant]
Cameron et al., “Type IV Collagen and Corneal Epithelial Adhesion and Migration,” Investigative Opthalmology & Visual Science 32:2766-2773 (1991). [cited by applicant]
Carlson et al., “Impact of Hyaluronic Acid-Containing Artificial Tear Products on Reepithelialization in an In Vivo Corneal Wound Model,” Journal of Ocular Pharmacology and Theapeutics, published online Feb. 2, 2018, ac… [cited by applicant]
Cavallaro et al., “Collagen Fabrics as Biomaterials”, Biotechnology and Bioengineering (1994) 43:781-791. [cited by applicant]
Chak et al., “A Review of Collagen Based Drug Delivery Systems,” International Journal of Pharmacy & Teaching and Practices (2013) 4(4):811-820. [cited by applicant]
Chan et al., “Photochemical crosslinking improves the physicochemical properties of collagen scaffolds”, J. Biomed. Mater. Res. (2005) 75A:689-701. [cited by applicant]
Chattopadhyay et al., “Peptides that anneal to natural collagen in vitro and ex vivo.,” Organic & Biomolecular Chemistry (2012) 10(30):5892-5897. [cited by applicant]
Chattopadhyay et al., “Anchoring a Cytoactive Factor in a Wound Bed Promotes Healing,” Journal of Tissue Engineering Regenerative Medicine (2014) 10(12):1012-1020. [cited by applicant]
Chattopadhyay et al., “Collagen-based biomaterials for wound healing,” Biopolymers (2014)101(8):821-833. [cited by applicant]
Chiang et al., “Treatment of Corneal Neovascularization,” EyeNet Oct. 2013:35-36. [cited by applicant]
Chopra et al., “Conformational implications of enzymatic proline hydroxylation in collagen,” Proceedings of the National Academy of Science of the United States of America (1982) 79(23):7180-7184. [cited by applicant]
Chung et al., “Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis,” The EMBO Journal (2004) 23(15):3020-3030. [cited by applicant]
Cooperman et al., “The immunogenicity of injectable collagen. I. A 1-year prospective study.” Journal of the American Academy of Dermatology (1984) 10(4):638-646. [cited by applicant]
Coudrillier et al., “Glaucoma-related Changes in the Mechanical Properties and Collagen Micro- architecture of the Human Sclera,” PLoS ONE (2015) (10):e0131396. [cited by applicant]
Dada et al., “Trabeculectomy With Combined Use of Subconjunctival Collagen Implant and Low-dose Mitomycin C,” J. Glaucoma 22:659-662 (2013) (Year: 2013). [cited by applicant]
Davis et al., “Regulation of Tissue Injury Responses by the Exposure of Matricryptic Sites within Extracellular Matrix Molecules,” American Journal of Patholofy (2000) 156(5):1489-1498. [cited by applicant]
Del Bouno et al., “Procol™, a New Technology for Drug Delivery,” Sustain Biotechnology. [cited by applicant]
Dua et al., “The collagen matrix of the human trabecular meshwork is an extension of the novel pre-Descemet's layer (Dua's layer),” British Journal of Ophthalmology (2014) 98(5):691-697. [cited by applicant]
Ellison et al., “Convenient Synthesis of Collagen-Related Tripeptides for Segment Condensation,” Peptide Science (2015) 104(6):676-681. [cited by applicant]
Epstein, Howard, “Cosmeceutical Vehicles,” Clininical Dermatology (2009) 27(5):453-460. [cited by applicant]
Erler, J.T., et al., “Lysyl oxidase is essential for hypoxia-induced metastasis,” Nature (2006) 440(27):1222-1226. [cited by applicant]
Erler et al., “Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the pre-metastatic niche,” Cancer Cell (2009) 15(1):35-44. [cited by applicant]
Fallas, et al., “Synthetic collagen mimics: self-assembly of homotrimers, heterotrimers and higher order structures,” Chem Soc Rev (2010) 39:3510-3527. [cited by applicant]
Fang et al., “Collagen as a double-edged sword in tumor progression,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine (2014) 35(4):2871-2882. [cited by applicant]
FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects, accessed Nov. 6, 2017, at https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm. [cited by applicant]
Fleischmajer et al., “Dermal collagen fibrils are hybrids of type 1 and type 3 collagen molecules,” Journal of Strutural Biology (1990) 105:162-169. [cited by applicant]
Frenkel et al., “Chondrocyte transplantation using a collagen bilayer matrix for cartilage repair,” The Journal of Bone and Joint Surgery (1997) 79-B:831-836. [cited by applicant]
Garg et al., “To Study the Efficacy of Difluprednate Opthalmic Emulsion and Prednisolone Acetate Opthalmic Suspension on Postoperative Inflammation in Cataract Surgery,” Journal of Clinical and Diagnostic Research (2016… [cited by applicant]
Gaudana et al., “Ocular Drug Delivery,” The AAPS Journal (2010) 12(3):348-360. [cited by applicant]
Gelse et al., “Collagens—structure, function, and biosynthesis,” Advanced Drug Delivery Reviews (2003) 55(12):1531-1546. [cited by applicant]
Giusti et al., “Collagen-based new bioartificial polymeric materials,” Biomaterials (1994) 15(15):1229-1233. [cited by applicant]
Gottlieb et al., “Self-Assembled collagen-like peptide fibers as templates for metallic nanowires,” Journal of Materials Chemistry (2008) 18:3865-3870. [cited by applicant]
Grabarek et al., “Zero-length crosslinking procedure with the use of active esters,” Analytical Biochemistry (1990) 185:131-135. [cited by applicant]
Granchi et al., “Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours,” ChemMedChem (2009) 4(10):1590-1594. [cited by applicant]
Hay, Elizabeth D., “Extracellular matrix,” Journal of Cell Biology (1981) 91(3):205-223. [cited by applicant]
Hodges et al., “Stereoelectronic and Steric Effects in the Collagen Triple Helix: Toward a Code for Strand Association,” J. A,. Chem. Soc. (2005) 127:15923-15932. [cited by applicant]
Hong et al., “Collagenase-Mediated Tissue Modeling of Corneal Ectasia and Collagen Cross-Linking Treatments,” Investigative Ophthalmology & Visual Science (2012) 53(4):2321-2327. [cited by applicant]
Huang et al., “Collagen: A potential factor involved in the pathogenesis of glaucoma,” Medical Science Monitor Basic Research (2013) 19:237-240. [cited by applicant]
Hulmes, D.J.S., “Collagen Diversity, Synthesis and Assembly,” in: Collagen: Structure and Mechanics (2008) pp. 15-47. [cited by applicant]
Jangamreddy et al., “Short peptide analogs as alternatives to collagen in pro-regenerative corneal implants,” Acta Biomaterialia (2018) 69:120-130. [cited by applicant]
Jones et al., “Analysis of structural design-features in collagen,” Journal of Molecular Biology (1991) 218:209-219. [cited by applicant]
Joseph et al., “Drug delivery to the eye: what benefits to nanocarriers offer?,” Nanomedicine (Lond.) (2017) 12(6):683-702. [cited by applicant]
Karlen et al., “Deep sclerectomy with collagen implant: medium term results,” Br. J. Ophthalmol. 83:6-11 (1999) (Year: 1999). [cited by applicant]
Karthikeyan et al., “The concept of ocular inserts as drug delivery systems: An overview,” Asian Journal of Pharmaceutics (2008) 2(4):192-200. [cited by applicant]
Kelkar et al., “Theranostics: combining imaging and therapy,” Bioconjugate Chem (2011) 22:1879-1903. [cited by applicant]
Kolenik et al., “Use of a Lyophilized Bovine Collagen Matrix in Postoperative Wound Healing,” Dermatol Surg (1999) 25:303-307. [cited by applicant]
Kumar et al., “A Nanostructured Synthetic Collagen Mimic for Hemostasis,” Biomacromolecules (2014) 15:1484-1490. [cited by applicant]
Kumar et al., “Polymer Gels: Perspectives and Applications,” Springer (2018). [cited by applicant]
Lauer et al., “Collagen in Cancer,” In: The Tumor Microenvironment, Springer-Verlag New York (2010) p. 477-507. [cited by applicant]
Lee et al., “Ocular Neovascularization: An Epidemiologic Review,” Survey of Ophthalmology (1998) 43(3):245-269. [cited by applicant]
Lee et al., “Enhanced chondrogenesis of mesenchymal stem cells in collagen mimetic peptide mediated microenvironment,” Tissue Engineering (2008) Part A 14(11):1843-1851. [cited by applicant]
Li et al., “Targeting and mimicking collagens via triple helical peptide assembly,” Curr. Opin. Chem. Biol. (2013) 17:968-975. [cited by applicant]
Lodish,et al., “Collagen: The Fibrous Proteins of the Matrix”, In: Molecular Cell Biology, 4th edition New York: W. H. Freeman, 2000, Section 22.3. [cited by applicant]
Luo et al., “Collagen-like peptides and peptide-polymer conjugates in the design of assembled materials,” Eur Polym J (2013) 49(10):2998-3009. [cited by applicant]
Lutolf et al., “Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering,” Nat Biotechnol (2005) 23(1):47-55. [cited by applicant]
Lynn et al., “Antigenicity and immunogenicity of Collagen,” Journal of Applied Biomedical Materials Research (2004) 718:343-354. [cited by applicant]
Ma et al., “Crosslinking strategies for preparation of extracellular matrix-derived cardiovascular scaffolds,” Regenerative Biomaterials (2014) 1(1):81-89. [cited by applicant]
Mattson et al., “A pratical approach to crosslinking,” Molecular Biology Reports (1993) 17(3):167-183. [cited by applicant]
Mix K., “Dissertation: Chemical Methods for Protein Modification and Cellular Delivery,” University of Wisconsin-Madison (2017). [cited by applicant]
Miyata et al., “Collagen Engineering for Biomaterial Use,” Clinical Materials (1992) 9:139-148. [cited by applicant]
Niyibizi et al., “Bone Type V Collagen: Chain Composition and Location of a Trypsin Cleavage Site,” Connective Tissue Research (1989) 20(1-4):247-250. [cited by applicant]
O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,” Cell (1997) 88(2):277-285. [cited by applicant]
Ortega et al., “New functional roles for non-collagenous domains of basement membrane collagens,” Journal Cell Science (2002)115:4201-4214. [cited by applicant]
Przbyla et al., “Higher-Order Assembly of Collagen Peptides into Nano- and Microscale Materials,” J. Biochemistry (2010) 49:4411-4419. [cited by applicant]
Rush et al., “Antagonizing c-Cbl Enhances EGFR-Dependent Corneal Epithelial Homeostasis,” Investigative Ophthalmology & Visual Science (2014) 55(8):4691-4699. [cited by applicant]
Rush et al., “Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition,” Investigative Ophthalmology & Visual Science (2016) … [cited by applicant]
Sakakibara, et al., “Synthesis of (Pro-Hyp-Gly)n of defined molecular weights Evidence for the stabilization of collagen triple helix by hydroxypyroline,” Biochimica et Biophysica Acta (1973) 303(1):198-202. [cited by applicant]
Schlegel et al., “De novo bone formation using bovine collagen and platelet-rich plasma,” Biomaterials (2004) 25(23):5387-5393. [cited by applicant]
Schuppan et al., “Collagens in the Liver Extracellular Matrix Bind Hepatocyte Growth Factor,” Gastroenterology (1998) 114(1):139-152. [cited by applicant]
Shoulders et al., “Collagen structure and stability,” Annual Review Biochememistry (2009) 78:929-958. [cited by applicant]
Siebler et al., “From Azidoproline to Functionalizable Collagen,” Chimia (2013) 67:891-895. [cited by applicant]
Staros et al., “Enchancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions,” Analytical Biochemistry (1986) 156:220-222. [cited by applicant]
Strauss et al., “Advances in the design and higher-order assembly of collagen mimetic peptides for regenerative medicine,” Current Opinion in Biotechnology (2017) 46:34-41. [cited by applicant]
Tanrikulu et al., “Peptide tessellation yields micron-scale collagen triple helices,” Nat. Chem. (2016) 8(12):1008-1014. [cited by applicant]
Timkovich, Russell, “Detection of the stable addition of carbodiimide to proteins,” Analytical Biochemistry (1977) 79:135-43. [cited by applicant]
Torricelli et al., “The Corneal Epithelial Basement Membrane: Structure, Function, and Disease,” Investigative Ophthalmology & Visual Science 54:6390-6400 (2013). [cited by applicant]
Wakitani, et al., “Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel,” The Journal of Bone Joint Surgery (1989) 71-B:74-80. [cited by applicant]
Wang et al., “Facile Modification of Collagen Directed by Collagen Mimetic Peptides,” J. Am. Chem. Soc. (2004):1.9. [cited by applicant]
Wipperman et al., “Evaluation and Management of Corneal Abrasions,” American Family Physician 87: 114-120 (2013) (Year: 2013). [cited by applicant]
Wollensak et al. “Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus”; American Journal of Ophthalmology, Ophthalmic (2003) 135(5):620-627. [cited by applicant]
Yamaguchi et al., “Negative regulation of transforming growth factor-β by the proteoglycan decorin,” Nature (1990) 346:281-284. [cited by applicant]
Yu et al., “Collagen mimetic peptides: progress towards functional applications,” Soft Matter (2011) 7:7927-7938. [cited by applicant]
Zhu et al., “Type IIA Procollagen Containing the Cyteine-rich Amino Propeptide Is Deposited in the Extracellular Matrix of Prechondrogenic Tissue and Binds to TGF-β1 and BMP-2,” Journal of Cell Biology (1999) 144(5):106… [cited by applicant]
Muller et al., “Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial,” Arthritis & Rheumatism, 58(12):3873-83 (2008). [cited by applicant]
Kontermann et al., “Bispecific antibodies,” Drug Discovery Today, 20(7):838-47 (2015). [cited by applicant]
Lee et al., “Collagen mimetic peptide-conjugated photopolymerizable PEG hydrogel,” Biomaterials, 27(30):5268-76 (2006). [cited by applicant]
Pandey et al., “Proline editing: a general and practical approach to the synthesis of functionally and structurally diverse peptides. Analysis of steric versus stereoelectronic effects of 4-substituted prolines on confo… [cited by applicant]
Ribeiro et al., “Intraocular Delivery of a Collagen Mimetic Peptide Repairs Retinal Ganglion Cell Axons in Chronic and Acute Injury Models,” Int J Mol Sci., 23(6):2911 (2022). [cited by applicant]